secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profusa, Inc. (PFSA)
CIK:        0001859807
Form:       8-K
Filed at:   2026-07-27T10:08:35+00:00
Accession:  0001213900-26-081560
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profusa signs non-binding term sheet to acquire diagnostics company with ~$111M revenue; appoints new CEO
--------------------------------------------------------------------------------

- Non-binding term sheet to acquire a private diagnostics/toxicology testing company; 2025 net revenues estimated at ~$111M (unaudited).
- Consideration: 19.99% of Profusa common stock plus non-voting convertible preferred stock; outstanding notes also exchanged for preferred.
- Concurrent ~$7M convertible note financing expected (12-month term, 9% OID, 7% interest, 18% default rate).
- Jack Stover appointed Executive Chairman and CEO; Ben Hwang becomes President and resigns from board; Liviu Goldenberg appointed independent director.
- Transaction subject to due diligence, definitive agreements, regulatory and shareholder approvals; no assurance of completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859807/000121390026081560/0001213900-26-081560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859807/000121390026081560/ea0298832-8k_profusa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-081560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer